首页 > 市场调查报告书 > 製药

生物标记循环系统

市场调查报告书

商品编码

1593527

心臟生物标记市场规模、份额和成长分析（按产品、应用、测试地点和地区）：产业预测（2024-2031）

Cardiac Biomarkers Market Size, Share, Growth Analysis, By Product (Troponin, CK-MB), By Application (Acute Coronary Syndrome, Myocardial Infarction), By Location of Testing, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月11日 | 出版商:

SkyQuest | 英文 199 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球心臟生物标记市场规模为94.2亿美元，从2023年的106.1亿美元成长到2031年的275.6亿美元，在预测期内（2024-2031年）预计复合年增长率为12.67%。年）。

在心臟病盛行率不断上升、人们对早期诊断益处的认识不断提高以及对个人化医疗的需求不断增长的推动下，心臟生物标记市场有望显着增长。在心臟受到压力或受伤时释放到血液中的生物标记在各种心臟疾病（包括心臟衰竭和心臟病发作）的诊断和治疗中发挥重要作用。生物标记检测的技术进步进一步刺激市场扩张。然而，挑战仍然存在，特别是先进生物标记测试的高成本和缺乏标准化，这可能导致测试结果的变异性。儘管存在这些障碍，整体市场前景仍然乐观。这是由持续的技术创新、对预防性医疗保健的浓厚兴趣以及不断上涨的医疗保健成本所推动的。随着情况的发展，心臟生物标记行业预计将稳定并成长，以满足对抗循环系统疾病的有效诊断解决方案不断增长的需求。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲
中东和非洲 (MEA)
- 波湾合作理事会(GCC) 国家
- 南非
- 其他中东/非洲

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Abbott
QuidelOrtho Corporation
Siemens AG
F. Hoffmann-La Roche Ltd.
Danaher Corporation
Biomerieux SA
Bio-Rad Laboratories, Inc.
Randox Laboratories Ltd.
Creative Diagnostics
Life Diagnostics
Thermo Fisher Scientific
Becton, Dickinson and Company
DiaSorin
Myriad RBM
Mindray Medical International Limited
ReLIA Diagnostic Systems
Merck KGaA
Quanterix Corporation
Eurofins Scientific
Inova Diagnostics

简介目录

Product Code: SQMIG35A2951

Global Cardiac Biomarkers Market size was valued at USD 9.42 billion in 2022 and is poised to grow from USD 10.61 billion in 2023 to USD 27.56 billion by 2031, growing at a CAGR of 12.67% during the forecast period (2024-2031).

The cardiac biomarkers market is poised for considerable growth, propelled by a rising prevalence of heart diseases, heightened awareness about the advantages of early diagnosis, and an increasing demand for personalized medicine. These biomarkers, released into the bloodstream during heart stress or damage, play a crucial role in diagnosing and managing various cardiac disorders, including heart failure and heart attacks. Technological advancements in biomarker detection are further stimulating market expansion. However, challenges persist, notably the high costs of advanced biomarker tests and a lack of standardization, which can result in inconsistencies in test outcomes. Despite these hurdles, the overall market outlook remains optimistic, driven by ongoing innovations, a strong focus on preventive healthcare, and escalating healthcare expenditures. As the landscape evolves, the cardiac biomarkers sector is expected to stabilize and thrive, catering to an increasing demand for effective diagnostic solutions in the fight against cardiovascular diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiac Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cardiac Biomarkers Market Segmental Analysis

Global Cardiac Biomarkers Market is segmented by Product, Application, Location of Testing, and Region. Based on Product, the market is segmented into Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others. Based on Application, the market is segmented into Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others. Based on Location of Testing, the market is segmented into Laboratory Testing, Point of Care Testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cardiac Biomarkers Market

The increasing emphasis on preventive healthcare and early diagnosis is a significant market driver for the global cardiac biomarkers market. As healthcare systems worldwide shift from reactive to proactive approaches, there is a growing demand for innovative diagnostic tools that can identify cardiovascular diseases at an early stage. This trend is fueled by rising awareness about heart disease prevalence and the economic burden associated with late-stage interventions. Moreover, advancements in biomarker technology and the integration of personalized medicine enable healthcare providers to offer tailored treatment plans, further promoting demand for cardiac biomarkers, thereby driving market growth.

Restraints in the Global Cardiac Biomarkers Market

One of the significant market restraints for the global cardiac biomarkers market is the ongoing challenges related to biomarker reliability and validation. The complexity of the biological processes involved in cardiovascular diseases makes it difficult to ensure that biomarkers are consistently reliable across diverse populations and clinical settings. This lack of standardization can lead to variability in test results, which hinders the widespread adoption of these diagnostic tools. Furthermore, regulatory hurdles and the lengthy validation process for new biomarkers can delay market entry and contribute to costly investments, ultimately restricting innovation and limiting the growth potential of the cardiac biomarkers sector.

Market Trends of the Global Cardiac Biomarkers Market

The Global Cardiac Biomarkers market is experiencing a notable trend towards the adoption of multi-biomarker panels, reflecting a shift from traditional single biomarker assessments. This approach allows for comprehensive evaluation of cardiovascular risk factors, encompassing stress, cardiac injury, and inflammation. As healthcare providers increasingly recognize the limitations of individual biomarkers, multi-biomarker methodologies are being explored to enhance risk stratification, particularly in complex cases where single markers may fall short. This trend is expected to drive innovation and growth in the market, as the demand for more accurate and holistic cardiovascular diagnostics continues to escalate.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Patent Analysis
Value Chain Analysis
Regulatory Analysis

Cardiac Biomarkers Market By Product

Market Overview
Troponin
CK-MB
Myoglobin
BNP & NT-proBNP
Others

Cardiac Biomarkers Market By Application

Market Overview
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others

Cardiac Biomarkers Market By Location of Testing

Market Overview
Laboratory Testing
Point of Care Testing

Cardiac Biomarkers Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Abbott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QuidelOrtho Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomerieux SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Randox Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Creative Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Life Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DiaSorin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad RBM
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mindray Medical International Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ReLIA Diagnostic Systems
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quanterix Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inova Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments